Limitation of Real World Evidence Highlighted by Physician Survey

Data collected from doctors, medical records, insurance claims databases and patient registries regarding use of medical products and disease conditions, called “Real World Evidence”, is often claimed to be reliable, robust and credible enough to support regulatory decisions. The 21st Century Cures Act requires FDA to create a process to use Real World Evidence (RWE) … Read more

Hacking Risks for Medical Devices with Internet Connectivity

Like any other internet-connected device, medical devices can be hacked, and the hacked device used to harm the individual dependent on it. Imagine someone controlling the pacemaker embedded in your body or the infusion pump giving you life-support. It’s no different from someone pointing a gun to your head, with similar outcome. The possibility no … Read more

What Can We Expect From FDA This Year Based What We Saw Last Year

Contrary to popular belief, most of what FDA does is not influenced much by political changes. The Agency has exhibited remarkable bipartisan support for most of its mandates, and exceptional resilience for almost all its activities. FDA review processes, compliance verification processes, most project management activities, safety monitoring activities, and most regulatory decisions affecting the … Read more

Almost All Clinical Trials Must be Registered with Clinicaltrials.gov

Almost all clinical trial initiated after 18th January 2017 must be registered with clinicaltrials.gov. Last week, NIH released a short checklist with detailed explainer for sponsors to determine if their trials must be registered with clinicaltrials.gov. An excellent explainer answers several common questions from sponsors regarding registration. Several useful facts are clarified for example, a Phase 1/Phase 2 must … Read more

“Should I Throw That Milk Away”, “May be Not”, says USDA

As much as 40% of food is thrown away every year by US consumers, retailers, restaurants, and other food operations, causing a loss of billions of dollars and negative environmental effects, according to USDA. An updated guidance from USDA explains the meaning of the various forms of food package dating and measures that must be taken before food is … Read more

Electronic Informed Consent Gets More Guidance from FDA

Last year FDA released a Guidance Document regarding use of electronic informed consent in clinical trials. The use of electronic informed consent adds practical and logistical challenges to the informed consent process despite the obvious benefits. This week, FDA published additional guidance on a Q&A format seemingly to address the key concerns raised by users. The key process … Read more

Real World Data For 505(b)(2) Development Programs

The 505(b)(2) regulatory pathway is primarily designed to get FDA approval of new indications of previously approved products. A provision in the 21st Century Cures Act, that became the law this week, could create a promising expedited approval pathway for 505(b)(2) products. Developers of such products need to conduct randomized clinical trials (RCTs) for the new indication. The … Read more

Adverse Events for Food and Cosmetics

This week FDA released a comprehensive list of all adverse events (AEs) reported to it related to food, dietary supplements and cosmetics for the last 12 years. This information was previously available only upon freedom of information request. The announcement “Why FDA Is Making Data Extracted from Reports of Adverse Events for Foods and Cosmetics … Read more

Will the New Law Boost Stem Cell Products and Other Regenerative Therapies?

Regenerative therapies are set to receive renewed attention and attractive regulatory incentives thanks to the 21st Century Cures Act (Cures Act) which is all but certain to become the law this week. The new law defines “regenerative medicine therapy” to be cell therapy, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or … Read more

Pharma’s Wish List for President Trump: Flexible Regulation

No one knows what President Trump would do next but we can certainly wish that the new perspective would possibly resolve a few issues that have challenged pharma-FDA relations for the last few years. There have been major disagreements over the rigid interpretation of regulations by FDA. Yesterday, the US Congress passed the 21st Century Cures … Read more